Adawi Kamal
Known title: CFO and Corporate SecretaryCIK: 0001788393
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
Transaction History
| FATE | ▲ Buy | Grant | 25,000 | $0 | 1/15/2026 | View on chart |
| FATE | ▲ Buy | Grant | 75,000 | $0 | 10/20/2025 | View on chart |
| XGN | ▼ Sell | Open Market | 9,297 | $18K | 3/4/2024 | View on chart |
| XGN | ▼ Sell | Open Market | 3,487 | $7K | 3/4/2024 | View on chart |
| XGN | ▲ Buy | Grant | 75,000 | $0 | 2/20/2024 | View on chart |
| XGN | ▼ Sell | Open Market | 6,738 | $13K | 2/6/2024 | View on chart |
| XGN | ▼ Sell | Open Market | 3,667 | $8K | 3/2/2023 | View on chart |
| XGN | ▲ Buy | Grant | 100,000 | $0 | 2/27/2023 | View on chart |
| XGN | ▼ Sell | Open Market | 5,821 | $16K | 2/8/2023 | View on chart |
| XGN | ▼ Sell | Tax Withholding | 3,241 | $23K | 3/1/2022 | View on chart |
| XGN | ▲ Buy | Grant | 63,500 | $0 | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.